ABOUT HASTEN BIOPHARMACEUTICAL CO., LTD

About Hasten

ROOTED IN CHINA, THINKING GLOBALLY

Scroll down

Hasten Biopharmaceutical Co., Ltd.(Hasten), which integrates R&D, production and commercialization and covers the whole industrial chain, was established in 2020. Hasten is jointly invested and established by CBC Group, Hefei Industry Investment Group and Feidong County, Hefei City. In April, 2023, Hasten received a US$315 million fundraising round co-led by CBC and Abu Dhabi sovereign wealth fund, Mubadala Investment Company, with participation from other institutional investors. Proceeds will be used to fund future acquisitions and business development of innovative pipeline assets.

We are committed to becoming a leader in the healthcare industry. We will work closely with our stakeholders such as relevant government institutions, medical and health professionals and industry partners to continuously drive the management ecosystem of chronic diseases & critical care related diseases, aiming to build a leading innovative medical and healthcare enterprise in China so as to benefit more patients and create social value.

2 overseas wholly-owned subsidiaries
1 production base
8 countries and regions in Pan-Asia,
mainland China & Switzerland patients benefited

OUR CULTURE

VISION

VISION

We are committed to becoming a leader in the healthcare industry that is trusted by customers, recognized by employees, and respected by society
MISSION

MISSION

Invest in science and talents,

continue to leverage

commercialization advantages,

provide high-quality medicines and

solutions that improve lives of people

and create social value.
VALUE

VALUE

Integrity

Agility

Innovation

Ownership
AMBITIONS

AMBITIONS

In the future, the unmet medical needs in the fields of chronic diseases and critical care related diseases will be growing and generate large marketing potentials.

Rooted in China with a global perspective, Hasten will connect the upstream and downstream industrial chains through the layout of "whole industry" and "globalization". We will enrich product structure and pipelines in diversified ways and rely on the broad medical and health platform and resources of CBC Group, as well as invest in science and talents to continuously leverage commercialization advantages.

We are committed to becoming a leader in the healthcare industry. We will work closely with our stakeholders such as relevant government institutions, medical and health professionals and industry partners to continuously drive the management ecosystem of chronic diseases & critical care related diseases, aiming to build a leading innovative medical and healthcare enterprise in China so as to benefit more patients and create social value.